KLOW Blend vs KPV
KLOW Blend (Multi-component research blend) and KPV (Alpha-MSH-derived tripeptide fragment) are documented as co-studied in the PeptiDex library. This page puts the two entries side by side on class, molecular weight, half-life, origin, mechanism and studied research areas — every value taken from the entry it belongs to.
Why these two are co-studied
Cross-referenced for research context — not a usage or combination recommendation.
At a glance
| Attribute | KLOW Blend | KPV |
|---|---|---|
| Compound class | Multi-component research blend | Alpha-MSH-derived tripeptide fragment |
| Research category | Healing & Recovery | Healing & Recovery |
| Length (amino acids) | Not documented | 3 amino acids |
| Molecular weight | Not documented | 342.43 g/mol |
| Half-life | Not documented | Not documented |
| Origin | KLOW is a marketed multi-component research blend. It is typically described as combining GHK-Cu (copper tripeptide), KPV (an alpha-MSH fragment), and a BPC-157 / TB-500 combination. Exact composition can vary by supplier and it is not a naturally occurring substance. | KPV is a synthetic tripeptide corresponding to the C-terminal three amino acids (lysine-proline-valine) of alpha-melanocyte-stimulating hormone (alpha-MSH), a naturally occurring melanocortin peptide. It is studied as a fragment that retains some anti-inflammatory properties of the parent hormone. |
“Not documented” means the PeptiDex entry records no value for that field. Nothing on this page is estimated, and no figure is carried over from one compound to the other.
How KLOW Blend works
As a blend, KLOW combines the documented properties of its components: GHK-Cu's copper-delivery and tissue-remodeling signaling, KPV's melanocortin-pathway anti-inflammatory activity, BPC-157's angiogenesis and growth-factor-related repair signaling, and TB-500's actin-regulation and cell-migration effects. These properties come from separate preclinical and cosmetic research; the combined formulation is not independently validated in controlled human trials.
How KPV works
KPV is reported in preclinical studies to exert anti-inflammatory effects, and research has explored both melanocortin-receptor-dependent signaling and intracellular actions independent of classic MSH pigmentation activity. It has been studied for downregulation of pro-inflammatory signaling such as NF-kB-associated pathways in cell and animal models of colitis. These findings derive from in-vitro and rodent research.
Mechanistic descriptions reflect published research-literature understanding and are quoted from each compound's own entry. Much peptide research is preclinical (in-vitro or animal-model); mechanism in humans may differ and is not established for many compounds.
Where each one appears in the literature
The research contexts each entry documents. Listing a research area is not a claim of efficacy or a therapeutic indication, and the two lists are not scored against each other.
KLOW Blend
KPV
What sets each apart
KLOW Blend
KLOW is a broader combination than two-component blends, pairing a copper cosmetic tripeptide and an anti-inflammatory MSH fragment with repair-focused peptides.
KPV
KPV is distinguished by its melanocortin-pathway anti-inflammatory focus, in contrast to the antimicrobial LL-37 or the tissue-repair emphasis of BPC-157 and TB-500.
Documented together as a research blend
Cross-referenced for research context — not a usage or combination recommendation.
Frequently asked questions
What is the KLOW blend and what does the name mean?
KLOW is a four-component research blend most commonly composed of KPV, GHK-Cu, BPC-157, and TB-500. The name is generally described as KPV added to the GLOW blend, where GLOW is GHK-Cu + BPC-157 + TB-500. Exact composition and ratios vary by supplier, so the vial's COA is the authoritative source.
What is each component in KLOW contributing?
In research terms, GHK-Cu (copper tripeptide) is studied for gene-expression modulation and tissue remodeling, BPC-157 for angiogenic and nitric-oxide signaling, TB-500 for actin dynamics and cell migration, and KPV for anti-inflammatory NF-kB modulation. The blend is used to study combined tissue-repair and inflammation pathways rather than any single target. All such effects are preclinical.
What is a typical KLOW vial composition?
One commonly cited configuration is an 80 mg vial containing roughly 50 mg GHK-Cu, 10 mg BPC-157, 10 mg TB-500, and 10 mg KPV. Other vendors use different totals and ratios, so this should be verified against the specific product's certificate of analysis rather than assumed.
Is KPV an approved drug?
No. KPV is a research compound with no regulatory approval, and its evidence base is preclinical. It is often included in tissue-repair research blends such as KLOW for its anti-inflammatory contribution.
What is KPV?
KPV is the C-terminal tripeptide (lysine-proline-valine) of alpha-melanocyte-stimulating hormone (alpha-MSH). It retains much of the parent hormone's anti-inflammatory activity while lacking its pigment-stimulating (melanocortin) effects. It is studied as a small anti-inflammatory peptide rather than as an approved therapeutic.
What is KPV studied for?
Preclinical research examines KPV for anti-inflammatory effects, particularly in models of intestinal inflammation and colitis, as well as skin inflammation. It is reported to enter cells and inhibit NF-kB signaling and pro-inflammatory cytokine production, and it can be transported into intestinal cells via the PepT1 transporter. No human clinical trials have confirmed these effects.
Answers are the ones published on each compound's own PeptiDex entry. They are educational summaries of research-literature context and are not medical advice.